What are the recommended methimazole dosing guidelines for treating hyperthyroidism in adults and children, including initial doses for mild versus moderate/severe disease, maintenance dosing, and pregnancy considerations?

Methimazole Dosing

For adults with hyperthyroidism, start methimazole at 15 mg daily for mild disease, 30-40 mg daily for moderate disease, or 60 mg daily for severe hyperthyroidism, then titrate to a maintenance dose of 5-15 mg daily once euthyroid. 1

Adult Dosing

Initial Therapy

The FDA-approved dosing provides clear stratification by disease severity 1:

• Mild hyperthyroidism: 15 mg daily
• Moderately severe hyperthyroidism: 30-40 mg daily
• Severe hyperthyroidism: 60 mg daily

Divide the total daily dose into 3 administrations at 8-hour intervals initially, though once-daily dosing is effective and improves adherence 2. Methimazole should be the preferred antithyroid drug in virtually all patients choosing medical therapy, except in specific circumstances detailed below 2.

Maintenance Dosing

Once thyroid hormone levels normalize (typically within 4-8 weeks), reduce the dose by approximately 50% to a maintenance range of 5-15 mg daily 1. Monitor thyroid function tests every 4-6 weeks during the titration phase, then every 2-3 months once stable 2.

Avoid "block-and-replace" regimens (continuing high-dose methimazole plus levothyroxine), as this approach increases adverse effects without improving outcomes 2.

Duration of Therapy

Treat for 12-18 months, then discontinue or reduce the dose to assess for remission 2. If TSH receptor antibodies remain elevated at 12-18 months, either continue methimazole for another 12 months or consider definitive therapy with radioactive iodine or thyroidectomy 2.

Pediatric Dosing

Initial Dose

Start at 0.4 mg/kg/day divided into 3 doses at 8-hour intervals 1. Practical weight-based dosing 2:

• Infants: 1.25 mg/day
• 1-5 years: 2.5-5 mg/day
• 5-10 years: 5-10 mg/day
• 10-18 years: 10-20 mg/day

For severe biochemical hyperthyroidism, doses 50-100% higher may be used initially 2.

Recent evidence suggests 0.3-0.5 mg/kg/day is suitable for mild disease, while 0.6-0.8 mg/kg/day is appropriate for moderate to severe disease. Doses of 0.8-1.0 mg/kg/day significantly increase adverse effects (41% vs 13-17%) without improving efficacy 3.

Maintenance Dose

Reduce to approximately half the initial dose once euthyroid 1. Continue therapy for 1-2 years before attempting discontinuation 2. If no remission occurs after this period, consider radioactive iodine or thyroidectomy 2.

Methimazole is strongly preferred over propylthiouracil in children due to the risk of severe hepatotoxicity with PTU 1.

Pregnancy Considerations

First Trimester

Switch to propylthiouracil during the first trimester due to methimazole's association with congenital malformations (aplasia cutis, choanal/esophageal atresia) 2. If pregnancy is detected while on methimazole, switch immediately to PTU using a conversion ratio of approximately 20-30:1 (e.g., 10-15 mg methimazole = 300 mg PTU) 2.

Second and Third Trimesters

Switch back to methimazole at the beginning of the second trimester to avoid PTU-related hepatotoxicity 2, 4. The Endocrine Society guideline recommends this switch despite potential difficulties in dose conversion 4.

Dosing Goals in Pregnancy

Use the lowest possible dose to maintain maternal free T4 at or slightly above the upper limit of the non-pregnant reference range, with TSH remaining suppressed 2. Monitor thyroid function monthly and adjust doses accordingly 2.

Lactation

Methimazole is safe during breastfeeding. Doses up to 10 mg/day are commonly used, with some practitioners allowing 15-20 mg/day if breastfeeding occurs 4-6 hours after administration 5. Monitor infant thyroid function at frequent (weekly or biweekly) intervals 1.

Critical Safety Monitoring

Before Starting Therapy

Obtain baseline complete blood count with differential, and liver function tests (bilirubin, transaminases, alkaline phosphatase) 2.

Patient Education

Instruct patients to stop methimazole immediately and contact you if they develop 2:

• Fever, sore throat, mouth sores (agranulocytosis warning)
• Jaundice, dark urine, light stools, right upper quadrant pain (hepatotoxicity)
• New rash, decreased urine output, hemoptysis (vasculitis)

Ongoing Monitoring

Check thyroid function every 4-6 weeks during dose titration, then every 2-3 months once stable. A rising TSH indicates the need for dose reduction 1.

Common Pitfalls

• Don't use block-and-replace therapy routinely - it increases adverse effects without improving remission rates
• Don't continue the same dose throughout pregnancy - thyroid dysfunction often improves as pregnancy progresses, requiring dose reduction
• Don't forget to switch from PTU to methimazole after the first trimester - PTU hepatotoxicity risk persists throughout pregnancy
• Don't use doses >0.8 mg/kg/day in children - this substantially increases adverse effects without improving outcomes 3